Study assessing safety of cobimetinib plus vemurafenib in patients with unresectable or metastatic melanoma: Real life data from the French temporary authorization for use program.
Phase of Trial: Phase IV
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Expanded access
- 02 Dec 2016 New trial record
- 11 Oct 2016 Results assessing safety presented at the 41st European Society for Medical Oncology Congress.